These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 19171609)

  • 21. Cost-effectiveness of neonatal screening for medium chain acyl-CoA dehydrogenase deficiency: the homogeneous population of The Netherlands.
    van der Hilst CS; Derks TG; Reijngoud DJ; Smit GP; TenVergert EM
    J Pediatr; 2007 Aug; 151(2):115-20, 120.e1-3. PubMed ID: 17643759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Healthcare use and costs of medium-chain acyl-CoA dehydrogenase deficiency in Australia: screening versus no screening.
    Haas M; Chaplin M; Joy P; Wiley V; Black C; Wilcken B
    J Pediatr; 2007 Aug; 151(2):121-6, 126.e1. PubMed ID: 17643760
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening of newborns and high-risk group of children for inborn metabolic disorders using tandem mass spectrometry in South Korea: a three-year report.
    Yoon HR; Lee KR; Kang S; Lee DH; Yoo HW; Min WK; Cho DH; Shin SM; Kim J; Song J; Yoon HJ; Seo S; Hahn SH
    Clin Chim Acta; 2005 Apr; 354(1-2):167-80. PubMed ID: 15748614
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expanded newborn screening using tandem mass spectrometry.
    Fearing MK; Levy HL
    Adv Pediatr; 2003; 50():81-111. PubMed ID: 14626484
    [No Abstract]   [Full Text] [Related]  

  • 25. Newborn screening for metabolic disorders.
    Marsden D; Larson C; Levy HL
    J Pediatr; 2006 May; 148(5):577-584. PubMed ID: 16737864
    [No Abstract]   [Full Text] [Related]  

  • 26. Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: a systematic review.
    Pandor A; Eastham J; Beverley C; Chilcott J; Paisley S
    Health Technol Assess; 2004 Mar; 8(12):iii, 1-121. PubMed ID: 14982654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: a cost-effectiveness analysis.
    Venditti LN; Venditti CP; Berry GT; Kaplan PB; Kaye EM; Glick H; Stanley CA
    Pediatrics; 2003 Nov; 112(5):1005-15. PubMed ID: 14595039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Neonatal screening in Denmark. Status and future perspectives].
    Simonsen H; Brandt NJ; Nørgaard-Pedersen B
    Ugeskr Laeger; 1998 Sep; 160(40):5777-82. PubMed ID: 9782755
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-benefit analysis: newborn screening for inborn errors of metabolism in Lebanon.
    Khneisser I; Adib S; Assaad S; Megarbane A; Karam P
    J Med Screen; 2015 Dec; 22(4):182-6. PubMed ID: 26062758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-benefit analysis of universal tandem mass spectrometry for newborn screening.
    Schoen EJ; Baker JC; Colby CJ; To TT
    Pediatrics; 2002 Oct; 110(4):781-6. PubMed ID: 12359795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing.
    Chace DH; Kalas TA
    Clin Biochem; 2005 Apr; 38(4):296-309. PubMed ID: 15766731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Newborn screening: current status.
    Arn PH
    Health Aff (Millwood); 2007; 26(2):559-66. PubMed ID: 17339686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-benefit analysis of newborn screening for galactosemia in the Philippines.
    Padilla CD; Dans LF; Estrada SC; Tamondong MR; Laceste JJ; Bernal RM
    Southeast Asian J Trop Med Public Health; 2003; 34 Suppl 3():215-20. PubMed ID: 15906739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of 4 neonatal screening strategies for cystic fibrosis.
    van den Akker-van Marle ME; Dankert HM; Verkerk PH; Dankert-Roelse JE
    Pediatrics; 2006 Sep; 118(3):896-905. PubMed ID: 16950979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of the US Environmental Protection Agency's SunWise program: sun protection education for young children.
    Kyle JW; Hammitt JK; Lim HW; Geller AC; Hall-Jordan LH; Maibach EW; De Fabo EC; Wagner MC
    Pediatrics; 2008 May; 121(5):e1074-84. PubMed ID: 18450850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Making the case for objective performance metrics in newborn screening by tandem mass spectrometry.
    Rinaldo P; Zafari S; Tortorelli S; Matern D
    Ment Retard Dev Disabil Res Rev; 2006; 12(4):255-61. PubMed ID: 17183573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development, validation and application of tandem mass spectrometry for screening of inborn metabolic disorders in Kuwaiti infants.
    Abdel-Hamid M; Tisocki K; Sharaf L; Ramadan D
    Med Princ Pract; 2007; 16(3):215-21. PubMed ID: 17409757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 26 years of external quality controls for the screening of congenital metabolic disorders in newborns--a summary of the results.
    Mathias D; Gebhard J; Wilhelm L; Schmidt-Gayk H; Mathias I
    Clin Lab; 2008; 54(3-4):103-8. PubMed ID: 18630741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Neonatal screening for congenital errors of metabolism by means of Tandem Mass: Italian experience].
    Cerone R; Cassanello M; Caruso U; Schiaffino MC; Lorini R
    Minerva Pediatr; 2007 Oct; 59(5):488-9. PubMed ID: 17947884
    [No Abstract]   [Full Text] [Related]  

  • 40. Newborn screening for all identifiable disorders with tandem mass spectrometry is cost effective: supporting arguments.
    Therrell BL; Buechner C
    Ann Acad Med Singap; 2008 Dec; 37(12 Suppl):32-4. PubMed ID: 19904443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.